ASHP Demands More Manufacturing of Ventilator Drugs for COVID-19

PharmaNewsIntelligence | April 07, 2020

ASHP recently urged the Trump administration to take action to address shortages of supportive ventilator drugs as the number of confirmed COVID-19 cases continues to rise. The American Society of Health-System Pharmacists (ASHP) recently called on the Trump Administration to address shortages of supportive ventilator drugs as COVID-19 continues to infect more patients.  In an official letter to Vice President Mike Pence, ASHP requested the administration release drugs from the Strategic National Stockpile to states hardest hit by COVID-19 and increase production of opioids to address shortages of medications needed to treat coronavirus patients. Ventilators are making their way to hospitals, but the drugs needed to operate them are gone or in short supply. Opioids, sedatives, and paralytics ensure the successful use of ventilators. But as patient admission increases, demand is outpacing supply and exhausting current allocations.

Spotlight

Merck & Co, known as MSD outside of the United States and Canada, is a global pharmaceutical company whose mission is to discover, develop and provide innovative products and services that save and improve lives around the world.


Other News

Dom Nicastro | April 03, 2020

Read More

Dom Nicastro | April 03, 2020

Read More

Dom Nicastro | April 03, 2020

Read More

Dom Nicastro | April 03, 2020

Read More

Spotlight

Merck & Co, known as MSD outside of the United States and Canada, is a global pharmaceutical company whose mission is to discover, develop and provide innovative products and services that save and improve lives around the world.

Resources